<div><p>Many in the phar&#173;ma world are hop&#173;ing &#8212; bet&#173;ter yet, ex&#173;pect&#173;ing &#8212; JAK in&#173;hibitors to pro&#173;vide one of the next big boons for the in&#173;dus&#173;try. <a href="https://endpts.com/pfizer-jumps-into-the-heated-phiii-race-for-new-wave-jak-inhibitors-but-safety-frets-loom-large/">Few have in&#173;vest&#173;ed</a> as <a href="https://endpts.com/pfizers-jak1-challenger-to-dupixent-shines-in-another-phiii-but-safety-issues-still-cast-a-shadow/">heav&#173;i&#173;ly</a> in this area as ...
</p>
            <a href="https://endpts.com/top-biotech-analyst-projects-a-gloomy-outlook-for-pfizers-jak-portfolio/" title="Top biotech analyst projects a gloomy outlook for Pfizer's JAK portfolio" class="epn_ux_button epn_more">READ MORE</a>
        </div>